HCC cell lines treated with an AURKA inhibitor (alisertib) or EZH2 inhibitor (gambogenic acid) exhibited impeded cell proliferation and decreased clone formation, migration, and invasion capacities. This evidence concerns the gene AURKA and hepatocellular carcinoma.